ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efimosfermin alfa

Also written as “Efimosfermin alfa”, “Efimosfermin” and “Efimosfermin Alfa”.

In GlaxoSmithKline’s pipeline, Fibroblast growth factor 21 (FGF21) analog. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases, Alcoholic · Obesity, led by 2 companies.

Drug pageEfimosfermin alfa: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 15, 202510 company-led studies, 7 open or runningAcquisition: GSK acquired Boston Pharmaceuticals, Jul 2025Next primary completion: Oct 13, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline97 open or runningphase 3since Oct 15, 2025May 5, 2021Oct 13, 2027phase 1 · NCT07358546
Novartisits history only10 open or runningphase 1since Feb 9, 2018Feb 9, 2018none ahead
  • Named in GlaxoSmithKline’s own pipeline as efimosfermin alfa GSK6519754, phase 3, as of Sep 30, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • AcquisitionGSK acquired Boston Pharmaceuticals, and with it efimosfermin, with the milestones and royalties owed to Novartis.Completed Jul 7, 2025 · Source: GSK, Jul 7, 2025

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 5, 2021First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT04880031 · 231 enrolled · United States
  2. Feb 29, 2024Named efimosfermin alfaINNProposed as its International Nonproprietary Name in WHO's List 130 · before, LLF580
  3. Mar 26, 2025Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06920043 · 42 planned · United States
  4. Jul 7, 2025GSK acquired Boston PharmaceuticalsAcquisitionWith it efimosfermin, with the milestones and royalties owed to Novartis · completed · GSK
  5. Oct 15, 20252 phase 3 studies in Non-alcoholic Fatty Liver DiseaseNCT07221227, NCT07221188
  6. Jan 5, 20262 phase 1 studies in Non-alcoholic Fatty Liver DiseaseNCT07335198, NCT07358546
  7. Jul 9, 20262 phase 3 studiesNCT07701993, NCT07704892
  8. Aug 21, 2026Phase 2 study in Liver Diseases, AlcoholicNCT07791043 · 274 planned · United States, Argentina, Canada and more

Ahead

  1. Oct 13, 2027Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07358546
  2. Mar 24, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07221188
  3. Mar 29, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07221227
  4. Jul 3, 2028Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06920043

TargetBeta

“Fibroblast growth factor 21 (FGF21) analog”the company's pipeline, read by Claude · source

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
pegozafermin89bio-incphase 38
efruxiferminNovo Nordiskphase 36
zalferminNovo Nordiskphase 210

Studies

All 9 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07791043Liver Diseases, Alcoholic · United States, Argentina, Canada and more2RecruitingAug 11, 2028274
NCT07704892Fibrosis · United States, Japan3RecruitingOct 16, 2030380
NCT07701993Fatty Liver · United States, Japan3RecruitingJun 23, 20331,740
NCT07358546Non-alcoholic Fatty Liver Disease · United States1RecruitingOct 13, 202732
NCT07335198Non-alcoholic Fatty Liver Disease · New Zealand1CompletedAug 13, 202630
NCT07221227Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more3RecruitingMar 29, 20281,200
NCT07221188Non-alcoholic Fatty Liver Disease · United States, Australia, France and more3RecruitingMar 24, 20281,250
NCT06920043Non-alcoholic Fatty Liver Disease · United States2RecruitingJul 3, 202842
NCT04880031Non-alcoholic Fatty Liver Disease · United States2CompletedOct 27, 2025231

How it is read

Names in the registry

  • “Efimosfermin alfa”, 7 entries
  • “Efimosfermin”, 2 entries
  • “Efimosfermin Alfa”, 1 entry
  • “LLF580”, 1 entry

Codes read as this program: BOS580.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.